Print

Active Biotech AB Interim Report January - September 2010

2010-10-27

  • Laquinimod ― Phase III trials proceeding as planned, results from Phase II extension study published in scientific journal
  • TASQ ― preparations ongoing for start of Phase III in first half of 2011
  • ANYARA ― ongoing phase III trial expected to be concluded in first half of 2012
  • 57-57 ― exploratory SLE clinical trial completed
  • ISI ― project continuing according to plan
  • RhuDex(TM) ― preparations for continued clinical development in progress
  • Net sales of SEK 8.5 M (7.7)
  • Operating loss of SEK 149.7 M (loss: 164.6)
  • Loss after tax SEK 156.8 M (loss: 165.1)
  • Loss per share for the period amounted to SEK 2.40 (loss: 2.90)

For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95

Göran Forsberg
VP Investor Relations & Business Development
Tel: +46 (0)46-19 11 54

Hans Kolam
CFO
Tel: +46 (0)46-19 20 44

Active Biotech AB
(Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00

This report is also available at www.activebiotech.com



pdfActive Biotech AB Interim Report January-September 2010



Back